Inmaculada Abreu-Alonso

Santa Cruz De Tenerife, CN, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

Real-World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA Registry.

Real-World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA Registry.

Journal: Alimentary pharmacology & therapeutics

Published: March 28, 2026

Impact of celiac disease on the clinical course of inflammatory bowel disease: CEL_EII study by GETECCU.

Impact of celiac disease on the clinical course of inflammatory bowel disease: CEL_EII study by GETECCU.

Journal: Therapeutic advances in gastroenterology

Published: January 28, 2026

Predictors of Steroid Failure and Outcomes of Rescue Therapy in Severe ICI-Induced Colitis: A Multicenter Study from GETECCU.

Predictors of Steroid Failure and Outcomes of Rescue Therapy in Severe ICI-Induced Colitis: A Multicenter Study from GETECCU.

Journal: Digestive diseases and sciences

Published: January 05, 2026

Post-Operative Recurrence of Colonic Crohn's Disease After Colectomy: The RESECOL Study by the Young Group of GETECCU.

Post-Operative Recurrence of Colonic Crohn's Disease After Colectomy: The RESECOL Study by the Young Group of GETECCU.

Journal: Alimentary pharmacology & therapeutics

Published: January 03, 2026

Improved appropriateness of electronic consultations in primary care with ongoing liver disease education.

Improved appropriateness of electronic consultations in primary care with ongoing liver disease education.

Journal: Journal of telemedicine and telecare

Published: December 08, 2025

Multicenter Spanish study on vedolizumab intravenous to subcutaneous switch in patients with inflammatory bowel disease in clinical remission.

Multicenter Spanish study on vedolizumab intravenous to subcutaneous switch in patients with inflammatory bowel disease in clinical remission.

Journal: Revista espanola de enfermedades digestivas

Published: September 29, 2025

Multicenter Spanish study on vedolizumab intravenous to subcutaneous switch in patients with inflammatory bowel disease in clinical remission.

Multicenter Spanish study on vedolizumab intravenous to subcutaneous switch in patients with inflammatory bowel disease in clinical remission.

Journal: Revista espanola de enfermedades digestivas

Published: September 29, 2025

Clinical, Endoscopic, and Histological Characteristics of Severe Immune Checkpoint Inhibitor-Induced Colitis.

Clinical, Endoscopic, and Histological Characteristics of Severe Immune Checkpoint Inhibitor-Induced Colitis.

Journal: Journal of clinical medicine

Published: September 24, 2025

[Translated article] Relationship between plasma concentrations of ustekinumab at week 8 and its effectiveness in patients with Crohn's disease.

[Translated article] Relationship between plasma concentrations of ustekinumab at week 8 and its effectiveness in patients with Crohn's disease.

Journal: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria

Published: July 31, 2025

Relationship between plasma concentrations of ustekinumab at week 8 and its effectiveness in patients with Crohn's disease.

Relationship between plasma concentrations of ustekinumab at week 8 and its effectiveness in patients with Crohn's disease.

Journal: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria

Published: July 31, 2025

Long-Term Outcomes Following Withdrawal of Anti-Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long-Term Study of GETECCU.

Long-Term Outcomes Following Withdrawal of Anti-Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long-Term Study of GETECCU.

Journal: Alimentary pharmacology & therapeutics

Published: January 14, 2025

Effect of invitation to colonoscopy versus faecal immunochemical test screening on colorectal cancer mortality (COLONPREV): a pragmatic, randomised, controlled, non-inferiority trial.

Effect of invitation to colonoscopy versus faecal immunochemical test screening on colorectal cancer mortality (COLONPREV): a pragmatic, randomised, controlled, non-inferiority trial.

Journal: Lancet (London, England)

Published: October 15, 2024

Showing 1-12 of 44

Last Updated: 09/26/2026